Allocation Concealment Versus Blinding: Two Safeguards People Keep Confusing

Allocation concealment and blinding are different safeguards that act at different moments. Concealment keeps whoever enrolls a patient from foreseeing the next assignment, protecting the comparability that randomization creates; blinding keeps patients, clinicians, or assessors from knowing the assignment once the trial is running, protecting against biased behavior and judgment. A trial can have one without the other, so good reports describe each separately.

Two safeguards, two moments

Allocation concealment and blinding both protect a trial from bias, but they act at different moments and stop different problems. Allocation concealment operates up to and at the instant of randomization: it keeps whoever is enrolling a patient from knowing which arm the next person will land in.

Blinding, sometimes called masking, operates after assignment. It keeps patients, clinicians, or outcome assessors from knowing which arm a person is in once the trial is underway. Reading a paper well starts with separating these two ideas rather than merging them.

What allocation concealment prevents

If the person recruiting patients can foresee the next assignment, they can steer sicker or healthier patients toward one arm, consciously or not. That quietly breaks the point of randomization, which is to make the groups comparable at baseline before anyone is treated.

Concealment is achieved with mechanisms such as a central randomization service or sequentially numbered, opaque, sealed envelopes. It is a one-time protection at the door. Crucially, it is always possible, even in trials that cannot be blinded, such as surgery compared with physiotherapy.

What blinding prevents

Blinding guards against what happens after the door. If patients know they received the active drug, they may report symptoms differently or seek other care. If treating clinicians know, they may adjust co-treatments. If outcome assessors know, they may judge subjective endpoints more generously. These are performance and detection bias.

Blinding is not always feasible, and its absence matters most for subjective outcomes and least for hard ones such as death. That is why the same missing blinding can be a serious problem in one trial and a minor one in another.

Why the two get confused

Both are often lumped together as blinding in casual reading, and older reports used the vague phrase double-blind without saying who was masked. But a trial can conceal allocation perfectly and still be open-label afterward, or be double-blind yet built on a predictable assignment sequence.

They are independent features, and each should be reported on its own. RoB 2 and other appraisal tools keep them in separate domains for exactly this reason, because they fail in different ways and matter for different outcomes.

What the empirical evidence shows

Studies comparing trials by methodological feature found that inadequate or unclear allocation concealment was associated with exaggerated treatment effects, with odds ratios inflated on the order of a third. Lack of double-blinding was also associated with exaggeration, though by a smaller margin.

The lesson is not that unconcealed trials are worthless. It is that their effects tend to run optimistic on average, so a careful reader treats the headline number as probably somewhat generous and discounts accordingly.

How to check a paper

Look for two separate statements. First, how was the allocation sequence concealed from the person enrolling patients, where central randomization is the strongest signal. Second, who exactly was blinded: participants, care providers, outcome assessors, or some subset of them.

If a report says double-blind but never says who, treat that as missing information rather than reassurance. And remember that an unblinded trial with a blinded outcome committee can still protect its endpoint even when it cannot protect the day-to-day experience of being in the trial.